Evidence map›Paper›PMID 36355430›Full record

ArticleCancer control : journal of the Moffitt Cancer Center

Impact of the COVID-19 Pandemic on a Cancer Fast-Track Programme.

M T Martínez, S Moragon, B Ortega-Morillo, J Montón-Bueno, S Simon, S Roselló, A Insa, A Viala, J Navarro, A Sanmartín and 15 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer control : journal of the Moffitt Cancer Center. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 1 institution in 1 country.

M T MartínezDepartment of Medical Oncology Department, Hospital Clínico Universitario, Biomedical Research Institute INCLIVA, University of Valencia, Valencia, Spain.
S MoragonDepartment of Medical Oncology Department, Hospital Clínico Universitario, Biomedical Research Institute INCLIVA, University of Valencia, Valencia, Spain.ORCID 0000-0001-6490-6977
B Ortega-MorilloDepartment of Medical Oncology Department, Hospital Clínico Universitario, Biomedical Research Institute INCLIVA, University of Valencia, Valencia, Spain.
J Montón-BuenoDepartment of Medical Oncology Department, Hospital Clínico Universitario, Biomedical Research Institute INCLIVA, University of Valencia, Valencia, Spain.
S SimonDepartment of Medical Oncology Department, Hospital Clínico Universitario, Biomedical Research Institute INCLIVA, University of Valencia, Valencia, Spain.
S RosellóDepartment of Medical Oncology Department, Hospital Clínico Universitario, Biomedical Research Institute INCLIVA, University of Valencia, Valencia, Spain.
A InsaDepartment of Medical Oncology Department, Hospital Clínico Universitario, Biomedical Research Institute INCLIVA, University of Valencia, Valencia, Spain.
A VialaDepartment of Medical Oncology Department, Hospital Clínico Universitario, Biomedical Research Institute INCLIVA, University of Valencia, Valencia, Spain.
J NavarroManagement Department, Hospital Clinico Universitario de Valencia, Biomedical Research Institute INCLIVA, University of Valencia, Valencia, Spain.
A SanmartínManagement Department, Hospital Clinico Universitario de Valencia, Biomedical Research Institute INCLIVA, University of Valencia, Valencia, Spain.
C FluixáAlfahuir Primare Care Center, Valencia, Spain.
A JulveDepartment of Radiodiagnosis, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain.
D SorianoDepartment of Radiodiagnosis, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain.
E BuchDepartment of Surgery, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain.ORCID 0000-0001-7800-9935
A PeñaDepartment of Medicine Digestive, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain.
J FrancoDepartment of Pneumology, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain.
J Martínez-JabaloyasDepartment of Urology, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain.
J MarcoDepartment of Otolaryngology, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain.
M J FornerDepartment of Internal Medicine, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain.
A CanoDepartment of Gynaecology, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain.
A SilvestreDepartment of Traumatology, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain.
A TeruelDepartment of Haematology, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain.
B BermejoDepartment of Medical Oncology Department, Hospital Clínico Universitario, Biomedical Research Institute INCLIVA, University of Valencia, Valencia, Spain.
A CervantesDepartment of Medical Oncology Department, Hospital Clínico Universitario, Biomedical Research Institute INCLIVA, University of Valencia, Valencia, Spain.
I Chirivella GonzalezDepartment of Medical Oncology Department, Hospital Clínico Universitario, Biomedical Research Institute INCLIVA, University of Valencia, Valencia, Spain.
Universitat de València · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe COVID-19 pandemic has disrupted many aspects of clinical practice in oncology, particularly regarding early cancer diagnosis, sparking public health concerns that possible delays could increase the proportion of patients diagnosed at advanced stages. In 2009, a cancer fast-track program (CFP) was implemented at the Clinico-Malvarrosa Health Department in Valencia, Spain with the aim of shortening waiting times between suspected cancer symptoms, diagnosis and therapy initiation.

objectivesThe study aimed to explore the effects of the COVID-19 pandemic on our cancer diagnosis fast-track program.

methodsThe program workflow (patients included and time periods) was analysed from the beginning of the state of alarm on March 16th, 2020 until March 15th, 2021. Data was compared with data from the same period of time from the year before (2019).

resultsDuring the pandemic year, 975 suspected cancer cases were submitted to the CFP. The number of submissions only decreased during times of highest COVID-19 incidence and stricter lockdown, and overall, referrals were slightly higher than in the previous 2 years. Cancer diagnosis was confirmed in 197 (24.1%) cases, among which 33% were urological, 23% breast, 16% gastrointestinal and 9% lung cancer. The median time from referral to specialist appointment was 13 days and diagnosis was reached at a median of 18 days. In confirmed cancer cases, treatment was started at around 30 days from time of diagnosis. In total, 61% of cancer disease was detected at early stage, 20% at locally advanced stage, and 19% at advanced stage, displaying time frames and case proportions similar to pre-pandemic years.

conclusionsOur program has been able to maintain normal flow and efficacy despite the challenges of the current pandemic, and has proven a reliable tool to help primary care physicians referring suspected cancer patients.

Indexed as

COVID-19Lung NeoplasmsCommunicable Disease ControlHumansPandemicsReferral and Consultationcancercancer fast track programCOVID-19 pandemicearly diagnosticprimary care

Identifiers

PMID36355430
PMCPMC9659548
OpenAlexW4309161831

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.